Influenza virus vaccine (Fluad) - Novartis Vaccines

Drug Profile

Influenza virus vaccine (Fluad) - Novartis Vaccines

Alternative Names: Chiromas; Fluad; Fluad Pediatric; Gripguard; Influpozzi Adiuvato; MF59-adjuvanted seasonal influenza vaccine (Fluad) - Novartis; Trivalent Influenza Vaccine (Fluad)- Novartis

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis Vaccines
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 29 Aug 2016 Influenza virus vaccine (Fluad) licensed to PaxVax in Switzerland
  • 26 Aug 2016 Adverse events and Immunogenicity data from a analyses of a total of 42 clinical trials released by Seqirus
  • 25 Aug 2016 Fluad® vaccine sub-licensed to Valneva for marketing in Austria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top